X T L Biopharmaceuticals Ltd. Daily Stock Analysis

Daily Stock Analysis, XTLB, X T L Biopharmaceuticals Ltd, priceseries

X T L Biopharmaceuticals Ltd. Daily Stock Analysis
Stock Information
Open
2.17
Close
2.29
High
2.30
Low
2.17
Previous Close
2.39
Daily Price Gain
-0.10
YTD High
3.00
YTD High Date
Jan 13, 2022
YTD Low
2.15
YTD Low Date
Feb 24, 2022
YTD Price Change
-0.59
YTD Gain
-20.49%
52 Week High
6.69
52 Week High Date
Jul 23, 2021
52 Week Low
2.15
52 Week Low Date
Feb 24, 2022
52 Week Price Change
-0.89
52 Week Gain
-27.99%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jun 21. 2017
2.83
Jul 13. 2017
3.34
15 Trading Days
18.17%
Link
LONG
Jul 6. 2018
1.99
Jul 9. 2018
2.31
1 Trading Days
16.33%
Link
LONG
Sep 25. 2018
1.89
Oct 9. 2018
2.05
9 Trading Days
8.51%
Link
LONG
Oct 10. 2018
2.37
Oct 17. 2018
2.53
5 Trading Days
6.67%
Link
LONG
Nov 8. 2018
2.75
Nov 9. 2018
2.97
1 Trading Days
7.90%
Link
LONG
May 4. 2020
1.23
May 13. 2020
1.33
5 Trading Days
7.89%
Link
LONG
Jun 12. 2020
1.38
Jun 17. 2020
1.44
3 Trading Days
5.00%
Link
LONG
Oct 29. 2020
2.20
Oct 30. 2020
2.42
1 Trading Days
10.23%
Link
LONG
Jul 21. 2021
3.92
Jul 26. 2021
4.20
3 Trading Days
7.02%
Link
LONG
Aug 19. 2021
3.98
Sep 3. 2021
4.72
11 Trading Days
18.68%
Link
Company Information
Stock Symbol
XTLB
Exchange
NasdaqCM
Company URL
http://www.xtlbio.com
Company Phone
972 9 955 7080
CEO
Joshua Levine
Headquarters
New York
Business Address
XTL BIOPHARMACEUTICALS LTD, C/O ALSTON & BIRD LLP, 90 PARK AVENUE, NEW YORK, NY 10016
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001023549
About

XTL Biopharmaceuticals Ltd is a biopharmaceutical company, which engages in the acquisition and development of pharmaceutical drugs. Its drug development program, focuses on the treatment of Systemic lupus erythematosus (SLE). The company was founded on March 9, 1993 and is headquartered in Raanana, Israel.

Description

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, is engaged in the acquisition and development of pharmaceutical products for the treatment of unmet medical needs. The company's lead drug candidate is hCDR1, a Phase II clinical trial product for the treatment of systemic lupus erythematosus related autoimmune process; and recombinant human erythropoietin (rHuEPO) for the treatment of multiple myeloma patients, as well as for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia. Its rHuEPO has also granted an orphan drug designation from the FDA for the treatment of multiple myeloma. The company is also developing SAM-101, a proprietary combination of antipsychotic drugs and a medicinal compound, which has completed Phase IIa clinical trials as a therapy for psychotic diseases with focus on schizophrenia. It has a licensing agreement with Yeda Research and Development Company for the development of hCDR1. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was founded in 1993 and is based in Herzliya, Israel.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading